Myeloid growth factor therapy in malignant lymphomas--a 5-year retrospective study from Hungary.
Myeloid growth factors help to prevent and cure neutropenic events in malignant lymphoma patients treated by chemotherapeutical regimens. Administering either filgrastim or pegfilgrastim, treatment schedule can be kept well and less dose reductions are needed, which results in better survival rates. The aim of this study was to examine the indications and the outcome of myeloid precursor therapy among our malignant lymphoma patients. Between 2003 and 2007, 249 malignant lymphoma patients received 1,655 cycles of different polychemotherapies. Myeloid growth factor therapy was administered in 138 cases by 65 patients, which meant 8.33% of all treatment cycles and 26.1% of all patients, respectively. As for the indications, prevention was more common than intervention (71.7% vs. 28.3%). By preventive usage of growths factors, two-thirds of threatening neutropenic events could be avoided. Side effects were uncommon and mild: grades I-II toxicity was observed in 31% of all treatments. Analyzing the risk factors for febrile neutropenia among patients who received myeloid growth factor therapy compared to those who did not, we found the incidence of comorbidities, hypoalbuminemia, advanced stage disease, and aggressive chemotherapies significantly different in the two groups. Interestingly, there was no significant difference regarding the median age and the incidence of low body surface area. Our observations support that myeloid precursor therapy is an effective and safe implement to prevent or treat neutropenia in high-risk malignant lymphoma patients.
Váróczy
László
L
3rd Department of Medicine, Institute for Internal Medicine, Medical and Health Science Center, University of Debrecen, Móricz Zs. krt. 22, 4032 Debrecen, Hungary. laszlo.varoczy@freemail.hu
Gergely
Lajos
L
Páyer
Edit
E
Miltényi
Zsófia
Z
Simon
Zsófia
Z
Illés
Arpád
A
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D005260:Female; D005334:Fever / Q000139:chemically induced / Q000517:prevention & control; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D006814:Hungary; D008223:Lymphoma / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009503:Neutropenia / Q000139:chemically induced / Q000517:prevention & control*; D011092:Polyethylene Glycols; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D012189:Retrospective Studies; D012307:Risk Factors; D016896:Treatment Outcome; D055815:Young Adult
D000970:Antineoplastic Agents; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; C455861:pegfilgrastim; D011092:Polyethylene Glycols; D000069585:Filgrastim
Transfusion. 2007 Jun;47(6):969-80
17524085
Clin Cornerstone. 2006;8 Suppl 5:S19-28
17379160
Blood. 1992 Sep 15;80(6):1430-6
1381626
J Clin Oncol. 1999 Dec;17(12):3835-49
10577857
J Clin Oncol. 1990 Sep;8(9):1598
2264856
Cancer. 2003 Dec 1;98(11):2402-9
14635075
Curr Opin Oncol. 2007 Jul;19(4):299-307
17545791
Eur J Cancer. 2006 Oct;42(15):2433-53
16750358
Cancer Control. 2001 Nov-Dec;8(6 Suppl 2):16-21
11760554
Crit Rev Oncol Hematol. 2003 Oct 15;48(Suppl):S39-47
14563520
Hematol Oncol. 2004 Sep;22(3):121-34
15991222
J Clin Oncol. 1990 Jun;8(6):963-77
2348230